source
- Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealTakeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza. In May, the US District Court in Massachusetts ruled…Endpoints · 2mo ago↗ source
- Nurix to work with Roche on BTK degrader in pact worth up to $2.3BRoche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B cell malignancies, with broader plans in immunology and neurology. The deal could be ...Endpoints · 2mo ago↗ source
- When it’s time to save a limb, novel clinic meets unhoused people where they areUnmet vascular needs can lead to limb loss among unhoused patients. An unusual Massachusetts General Hospital program meets patients where they are.